Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
Biogen(BIIB) stock is priced at $176.84, giving the company a market capitalization of 25.94B. It carries a P/E multiple of 16.61.
During the trading session on 2025-12-01, Biogen(BIIB) shares reached a daily high of $181.78 and a low of $176.00. At a current price of $176.84, the stock is +0.5% higher than the low and still -2.7% under the high.
Trading activity shows a volume of 1M, compared to an average daily volume of 2.16M.
Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $185.17 and a low of $110.04.
Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $185.17 and a low of $110.04.
BIIB News
Biogen (BIIB) just announced a new research partnership with Dayra Therapeutics focused on developing oral macrocyclic peptides for immunological conditions. Th...
Biogen Inc.‘s (NASDAQ:BIIB) partner Eisai Co., Ltd, on Friday filed a new drug application for Leqembi (lecanemab) seeking approval for a subcutaneous formulati...
Eisai Co. (ESAIY) and Biogen (BIIB) announced that Eisai has completed the rolling submission of the Supplemental Biologics License Application to the U.S. FDA...
Analyst ratings
50%
of 36 ratingsMore BIIB News
In November 2025, Biogen and Dayra Therapeutics announced a research collaboration to develop oral macrocyclic peptide therapies for immunological disorders, wi...
News Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps Licensing Novo Nordisk (NVO) stock toppled Monday after its weight-loss pill f...
